Correction Continues after Big Move - BrokerBank Securities, Inc.
NEW YORK, May 21, 2015 /PRNewswire/ -- Prima Biomed Ltd. (NASDAQ: PBMD) a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer, recently announced that the final CVac data from the Phase II CAN-003 ovarian cancer clinical trial has shown a clear trend for a clinically meaningful improvement in Overall Survival ("OS") over standard of care ("SOC") in second remission patients.
In the group of second remission patients (n=20), the median for standard of care ("SOC") patients was 25.53 months, which is consistent with current literature. By comparison, for patients treated with CVac a median has still not yet been reached after 42 months with study completion and closure. This suggests a striking improvement with a hazard ratio1 = 0.17 (95%CI: 0.02, 1.44; p=0.07). This implies at least a 16 months median survival advantage for second remission patients when treated with CVac.
The news sparked a rally of nearly 270% to close Wednesday trading session. Early in trading today the stock is trading down.
For a more detailed research report with analyst comments and recommendation on Prima Biomed Ltd. please follow the link. There is no cost obligation required to view analyst brief.
http://bit.ly/-PBMD-AnalystReport
Copy and paste to browser may be required.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report. This document, article or report is written a 3rd party research analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Related Links
http://www.brokerbanksecurities.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article